bioAffinity Technologies Regains Nasdaq Compliance After Bid Price Recovery
Event summary
- bioAffinity Technologies received written notice from Nasdaq on September 8, 2026, confirming compliance with listing requirements.
- The company met the $1.00 minimum bid price rule (Listing Rule 5550(a)(2)) and rights/warrants rule (Listing Rule 5560(a)).
- Nasdaq Hearings Panel hearing previously scheduled for non-compliance was canceled.
- CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 99% negative predictive value in clinical trials.
The big picture
bioAffinity Technologies' regain of Nasdaq compliance is a critical milestone for maintaining market access and investor confidence. The company's focus on noninvasive diagnostics aligns with broader industry trends toward early disease detection and reduced reliance on invasive procedures. The strategic importance of sustaining compliance cannot be overstated, as it directly impacts the company's ability to raise capital and expand its commercial reach.
What we're watching
- Financial Stability
- How bioAffinity Technologies will sustain its stock price above the $1.00 threshold to maintain Nasdaq compliance.
- Regulatory Oversight
- Whether the company can navigate ongoing regulatory requirements for its CyPath Lung test under CLIA oversight.
- Commercial Adoption
- The pace at which bioAffinity Technologies can achieve broader commercial adoption of CyPath Lung.
Related topics